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Effects of antiplatelet therapy after stroke due to intracerebral 
haemorrhage (RESTART): a randomised, open-label trial 
RESTART Collaboration*
Summary
Background Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, 
although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of 
intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, 
but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects 
of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of 
occlusive vascular events.
Methods The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-
label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were 
taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when 
they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised 
randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We 
followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. 
We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for 
minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627).
Findings Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) 
after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet 
therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 
268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 
23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; 
p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared 
with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants 
allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid 
antiplatelet therapy (1·02 [0·65–1·60]; p=0·92).
Interpretation These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage 
with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when 
they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to 
exceed the established benefits of antiplatelet therapy for secondary prevention.
Funding British Heart Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Adults with stroke due to spontaneous intracerebral 
haemorrhage often have a history of occlusive vascular 
disease, such as myocardial infarction or ischaemic 
stroke.1 Consequently, at least a third of adults in 
high-income countries are taking oral antithrombotic 
(anti platelet or anticoagulant) drugs at the onset of 
intracerebral haemorrhage.2 Generally, antithrombotic 
drugs are immediately discontinued because of the risk of 
early haematoma growth. Discontinuation of these drugs 
is often permanent because of the perceived risk of 
recurrent intracerebral haemorrhage. However, the risk of 
occlusive vascular events might be higher,3 so resumption 
of antithrombotic therapy might be beneficial overall.
Results of randomised trials have found a favourable 
balance of the benefits and risks of antiplatelet and 
anticoagulant therapy for the secondary prevention of 
occlusive vascular disease for a variety of conditions, but 
these trials excluded people with a history of major 
bleeding.4–6 Therefore, no published randomised trials 
are available on whether long-term antithrombotic 
therapy is safe or beneficial for survivors of intracerebral 
haemorrhage overall,7 or in subgroups who are at higher 
risk of bleeding, such as people with lobar intracerebral 
haemorrhage.1
The use of antiplatelet therapy for about 2 days did 
not result in adverse effects for patients who had been 
enrolled in randomised trials of aspirin, without 
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knowing their stroke was due to intracerebral haemor-
rhage.8 In the longer term (months to years), findings 
from a systematic review and meta-analysis9 of observa-
tional studies of patients with any type of intracranial 
haemorrhage (ie, intracerebral, sub arachnoid, or subdural 
haemor rhage) showed lower risks of occlusive vascular 
events and no difference in haemorrhagic events 
associated with resumption  compared with avoidance 
of antiplatelet therapy. Small, non-randomised observa-
tional studies of patients with intracerebral haemor-
rhage have reported similar associations with starting 
antiplatelet therapy compared with its avoidance.10–14 
Because of the paucity of evidence, no guidelines with 
strong recommendations about long-term antiplatelet 
therapy after intracerebral haemorrhage are available,15,16 
so variations in clinical practice occur.3 Therefore, 
randomised controlled trials are needed to establish 
whether to use antiplatelet therapy after intracerebral 
haemorrhage.7
We initiated the REstart or STop Antithrombotics 
Randomised Trial (RESTART) with the aim of esti-
mating the relative and absolute effects of starting 
versus avoiding antiplatelet therapy on recurrent 
symptomatic intracerebral haemorrhage and whether 
this risk might exceed any reduction of occlusive 
vascular events.17.
Methods
Study design
RESTART was an investigator-led, pragmatic, multicentre, 
prospective, randomised, open-label, blinded endpoint, 
parallel-group trial in 122 hospitals in the UK. The Scotland 
A Research Ethics Committee approved the trial protocol 
(Nov 2, 2012).17 The trial co-sponsors were the University of 
Edinburgh and National Health Service Lothian Health 
Board. The patient reference group for the Research 
to Understand Stroke due to Haemorrhage (RUSH) 
programme reviewed the study materials and progress. 
The trial steering committee and co-sponsors approved the 
trial protocol and the statistical analysis plan.17,18
Participants
We included adults (≥18 years) who had survived at 
least 24 h after spontaneous intracerebral haemorrhage 
confirmed by brain imaging and were taking anti-
thrombotic (antiplatelet or anticoagulant) therapy for the 
prevention of occlusive vascular disease at the onset of 
intracerebral haemor rhage, after which therapy was 
discontinued. Patients were ineligible if the intracerebral 
haemorrhage was attributable to preceding head injury, 
haemorrhagic transformation of an ischaemic stroke, or 
intracranial haemorrhage without intracerebral haemor-
rhage; if they were still taking antithrombotic therapy at 
Research in context
Evidence before this study
The Antithrombotic Trialists’ Collaboration meta-analysis of 
randomised controlled trials found that aspirin use for the 
secondary prevention of occlusive vascular disease reduces risk of 
major vascular events, even though it might increase the risk of 
intracranial haemorrhage (a composite of intracerebral, 
subarachnoid, or subdural haemorrhages). However, these trials 
excluded patients with intracerebral haemorrhage, the 
commonest subtype of intracranial haemorrhage with the worst 
outcome. We searched the Cochrane Stroke Group Register, 
the Cochrane Central Register of Controlled Trials, Ovid MEDLINE 
(from 1948), Ovid Embase (from 1980), online registries of 
clinical trials, and bibliographies of relevant publications on 
Jan 28, 2019, (appendix) for randomised controlled trials of 
starting versus avoiding antiplatelet therapy after intracerebral 
haemorrhage, from database inception until Jan 28, 2019, 
without language restrictions. We found no completed 
randomised controlled trials. A meta-analysis of observational 
studies found no difference in the risk of haemorrhagic events 
and a lower risk of occlusive vascular events associated with 
antiplatelet therapy resumption after any type of intracranial 
haemorrhage.
Added value of this study
The REstart or STop Antithrombotics Randomised Trial 
(RESTART) is the first randomised controlled trial comparing 
the effects of starting versus avoiding antiplatelet therapy for 
patients with previous intracerebral haemorrhage that occurred 
while taking antithrombotic (antiplatelet or anticoagulant) 
therapy. Participants allocated to start antiplatelet therapy 
experienced proportionally (but not statistically) fewer 
recurrences of intracerebral haemorrhage (adjusted hazard ratio 
0·51 [95% CI 0·25–1·03]; p=0·060), fewer major haemorrhagic 
events (0·71 [0·39–1·30]; p=0·27), and similar numbers of 
major occlusive vascular events (1·02 [0·65–1·60]; p=0·92), 
compared with participants allocated to avoid antiplatelet 
therapy. These results exclude all but a very modest increase in 
the risk of recurrent intracerebral haemorrhage with 
antiplatelet therapy. The risk of recurrent intracerebral 
haemorrhage is probably too small to exceed the established 
benefits of antiplatelet therapy for the secondary prevention of 
occlusive vascular disease.
Implications of all the available evidence
RESTART’s findings provide reassurance about the safety of 
antiplatelet therapy after intracerebral haemorrhage that 
occurred while taking antithrombotic therapy. Replication of 
these findings and investigation of the possibility that 
antiplatelet therapy reduces the risk of recurrent intracerebral 
haemorrhage require further investigation in ongoing 
randomised trials (RESTART-Fr NCT02966119 and STATICH 
NCT03186729), a subsequent meta-analysis of RESTART, 
and an adequately powered definitive randomised 
controlled trial.
For more on the 
RUSH programme see 
www.RUSH.ed.ac.uk
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the time of consent (ie, after intracerebral haemorrhage); 
if they were pregnant, breastfeeding, or of childbearing 
age and not taking contraception; or if they or their carer 
was unable to understand spoken or written English. 
Patients, or their nearest relative or representative if the 
patient did not have mental capacity, provided written 
informed consent in inpatient or outpatient hospital 
settings. Participants could be enrolled if they or their 
nearest relative, and their physician in secondary care, 
were uncertain about whether to start or avoid antiplatelet 
therapy and had consented, in which case randomisation 
was done at least 24 h after stroke symptom onset.17
Randomisation and masking
Investigators supplied complete information about 
participants’ demographics, comorbidities, functional 
status, previous antithrombotic therapy, intracerebral 
haemorrhage, and their preferred antiplatelet therapy into 
a database via a secure web interface with in-built validation 
to ensure complete baseline data before randomisation. A 
central computerised randomisation system incorporating 
a minimisation algorithm randomly assigned participants 
(1:1) to start or avoid antiplatelet therapy. The algorithm 
randomly allocated the first participant with a probability 
of 0·5 to one group of the trial. Thereafter, adaptive 
stratification (ie, minimisation) allocated each subsequent 
participant with a probability of 0·8 to the group that 
minimised differences between the two groups of the 
trial with respect to five baseline variables: qualifying 
intracerebral haemorrhage location (lobar vs non-lobar); 
time since symptom onset (1–6 days, 7–30 days, >30 days); 
antiplatelet therapy preferred by the patient’s physician 
if allocated to start (aspirin alone vs other antiplatelet 
therapy); participant age at randomisation (<70 years 
vs ≥70 years); and predicted probability of being alive 
and independent at 6 months (<0·15 vs ≥0·15).19 The 
five variables were weighted equally, and the weights 
were constant over the duration of recruitment. The 
web interface displayed each participant’s unique study 
identification number and their allocation to either 
starting or avoiding antiplatelet therapy, which was also 
sent in an email to all investigators at the hospital site, 
having been concealed until that point. If the participant 
was allocated to start antiplatelet therapy, the system 
reminded investigators to prescribe the prespecified pre-
ferred antiplatelet therapy within 24 h.
Treatment allocation was open to participants, the 
clinicians caring for them in primary and secondary 
care, and local investigators. Staff following up the 
participants at the trial coordinating centre were 
masked to treatment allocation. Outcome event adjudi-
cators were masked to participant identity, treatment 
allocation, and drug use.
Procedures
Participants who had not already been imaged with MRI 
but complied with the trial’s MRI protocol, and who were 
able and willing to undergo brain MRI, provided informed 
consent and had a brain MRI scan before randomisation. 
After randomisation, anyone of a panel of consultant 
neuro radiologists (PMW, DPM, DM, PB, JCduP, or YJ), 
who was masked to treatment allocation, used the web-
based Systematic Image Review System tool to review 
anonymised DICOM images of diagnostic brain CT or 
MRI to confirm or refute eligibility and to support the 
adjudication of cerebral outcome events. 
The intervention of starting antiplatelet therapy was 
restricted to the use of one or more of oral aspirin, 
dipyridamole, or clopidogrel, begun within 24 h of 
randomisation with doses determined at the discretion of 
the consultant responsible for the participant. The 
comparator was a policy of avoiding antiplatelet therapy 
(ie, no placebo group). Participants were permitted to start 
or discontinue antiplatelet or anticoagulant therapy if 
clinically indicated by events during follow-up, regardless 
of treatment allocation. We measured adherence after 
randomisation regardless of treatment allocation by 
recording antiplatelet therapy use before the first out-
come event according to the preceding clinic or hospital 
discharge form or follow-up questionnaire. We collected 
information about blood-pressure lowering drugs and 
blood pressure control at discharge and during follow-up.
We followed up participants by sending a postal 
questionnaire to their primary care practitioners (who 
hold a comprehensive lifelong medical record for each 
patient registered with them), followed by a postal 
questionnaire to surviving participants (or carers) who 
had not withdrawn, to check vital status, medication use, 
modified Rankin scale score, and the occurrence of 
outcomes. We sent questionnaires at set intervals after 
randomisation (6 months or 1 year, 2 years, 3 years, 
4 years, and 5 years). Participants who did not respond to 
the questionnaire were interviewed by phone.20,21
We recorded serious adverse events (that were neither 
an outcome event nor an expected complication of 
stroke) via investigators if they occurred before hospital 
discharge or via primary care practitioners’ annual 
reports of hospital admissions. Investigators reported 
protocol deviations and violations to the trial coordinating 
centre and the sponsor.
Monitoring included central statistical monitoring of 
trial conduct, data quality, and participant safety, 
supplemented by triggered onsite monitoring visits 
if required and detailed source data verification at 
the trial coordinating centre. All baseline and outcome 
data underwent completeness, range, consistency, 
validation, and logic checks within the web-based case 
report forms.
Outcomes
The primary outcome was fatal or non-fatal radiographically 
or pathologically proven recurrent symptomatic intra-
cerebral haemorrhage assessed in all participants (except 
one participant who withdrew before the first follow-up).17 
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The secondary outcomes were a composite of all major 
haemorrhagic events and a composite of all major occlusive 
vascular events.17 Major haemorrhagic events included 
recurrent symptomatic intracerebral haemorrhage (pri-
mary out come), other forms of symptomatic spontaneous 
or traumatic intracranial haemorrhage, and symptomatic 
major extracranial haemorrhage at any site (requiring 
transfusion or endoscopic treatment or surgery, or resulting 
in death within 30 days).18 Major occlusive vascular events 
were ischaemic stroke; myocardial infarction; mesenteric 
ischaemia; peripheral arterial occlusion; deep vein 
thrombosis; pulmonary embolism; and carotid, coronary, 
or peripheral arterial revascularisation procedures.18 The 
composite secondary outcome of all major haemorrhagic 
or occlusive vascular events combined these two composite 
outcomes.18 In the protocol, we had specified a composite 
secondary outcome of all major vascular events defined 
by the Antithrombotic Trialists’ Collaboration (non-fatal 
myocardial infarction, non-fatal stroke [ischaemic, haemor-
rhagic, or uncertain cause], or death from a vascular cause).4,17
Two consultant neurologists (WNW and MRM) at the 
trial coordinating centre were internal assessors of reports 
of every outcome event, masked to treatment allocation 
and use of antithrombotic therapy, using all available source 
documentation including clinical records, death certificates, 
autopsy reports, imaging reports, outpatient clinic letters, 
and hospital discharge summaries. One consultant 
neurologist (TG) was an external assessor and reviewed 
the same information on a random sample of 25 internally 
assessed events. He agreed with the internal assessors for 
24 (96%) events (appendix) and, therefore, the internal 
assessors’ categorisations remained final. Standardised 
definitions guided the final categorisation of outcomes.22,23
Statistical analysis
We aimed to recruit 720 participants and follow them up 
for at least 2 years to cover several combinations of 
published estimates of the primary outcome event rate 
in cohort studies (1·8–7·4% per year)1 and an up to four-
times  proportional increase in the absolute risk of the 
primary outcome with the use of antiplatelet therapy in 
observational studies.10–12 For example, at the 5% signi-
ficance level, the trial would have 90% power to detect a 
doubling of a primary outcome event rate of 4·5% per 
year, or 93% power to detect a four-times increase of a 
rate of 1% per year.17
Throughout the recruitment period, unmasked trial 
statisticians supplied the independent data monitoring 
committee with analyses of the accumulating baseline 
and follow-up data in strict confidence at least once every 
year, so that they could assess trial conduct, safety, and 
efficacy, and make recommendations to the trial steering 
committee. No formal fixed schedule of interim analyses 
was followed, but the data monitoring committee could 
advise the chairman of the trial steering committee if 
they thought the randomised comparisons provided 
proof beyond reasonable doubt that, for some patients, 
anti platelet therapy was clearly indicated or contraindi-
cated in clinical practice.
Without reference to data by randomised allocation or 
input from the unmasked trial statistician, the masked 
trial statistician (GDM) and chief investigator (RA-SS) 
prepared a statistical analysis plan that was approved by 
the trial steering committee before database lock, and 
then published.18
We estimated the survival function in each treatment 
group using a Kaplan-Meier survival analysis of time 
to first occurrence of a primary or secondary outcome 
event during all available follow-up after randomisation, 
censored at death unrelated to an outcome event or last 
available follow-up. We quantified completeness of follow-
up as the proportion of participants with a complete 
follow-up questionnaire at each planned interval after Figure 1: Trial profile
562 participants consented  
537 randomly assigned
25 were not randomised 
6 ineligible
7 health condition deteriorated 
11 clinicians, or participant or carer not
uncertain about antiplatelet drug use 
1 consented after end of recruitment 
 
268 assigned to start antiplatelet 
therapy 
259 received antiplatelet therapy 
before first event
6 did not receive antiplatelet 
therapy before first event
3 died before discharge 
265 had first follow-up 
268 analysed 
267 had first follow-up 
264 did not receive antiplatelet 
therapy before first event
4 received antiplatelet therapy 
before first event
 
269 assigned to avoid antiplatelet 
therapy  
268 analysed 
1 withdrew from follow-up 
1 died before discharge 
9 ineligble
3 anticoagulant use 
at randomisation
3 haemorrhagic 
transformation of 
ischaemic stroke
2 subarachnoid 
haemorrhage
1 meningioma
7 ineligble
1 anticoagulant use 
at randomisation
2 haemorrhagic 
transformation of 
ischaemic stroke
3 intraventricular 
haemorrhage
1 subarachnoid 
haemorrhage
See Online for appendix
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randomisation, and as the proportion of the planned 
duration of follow-up that was observed.24 We quantified 
absolute differences in annual event rates. After assessing 
the proportional hazards assumption graphically and 
including a treatment by log(time) interaction, we 
compared the survival functions by allocated treatment 
using the log-rank test. We constructed an unadjusted Cox 
proportional hazards regression model and a second 
model adjusted for all five covariates included in the 
minimisation algorithm (which was the primary method 
of analysis) to calculate the hazard ratios (HRs). We 
prespecified a hierarchical testing of the primary outcome, 
key secondary outcomes, and other secondary outcomes, 
so we did not adjust the threshold of statistical significance 
for multiplicity.18 We used the Mann–Whitney test to 
compare group summaries of modified Rankin scale 
scores by randomised group. We did sensitivity analyses 
by adding symptomatic stroke of uncertain subtype or 
deaths of undetermined cause to the primary outcome, 
and by calculating the cumulative incidence of all major 
haemorrhagic or occlusive vascular events.
We did prespecified exploratory subgroup analyses of 
the primary and secondary outcomes with statistical tests 
of interaction to estimate heterogeneity of treatment effect 
between the prespecified subgroups: the five covariates 
used by the minimisation algorithm, antithrombotic 
therapy before intracerebral haemorrhage, and history of 
atrial fibrillation.
The unmasked trial statistician (JS) did all statistical 
analyses with SAS version 9.4.
This trial is registered with ISRCTN (number 
ISRCTN71907627).
Role of the funding source
The funder of this study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing and decision to publish this Article. The 
corresponding author had full access to all data in the 
trial and had final responsibility for the decision to 
submit for publication.
Results
Between May 22, 2013, and May 31, 2018, 562 participants 
consented to participate in the study, from 104 of 
122 activated hospital sites (appendix, figure 1). 
20 participants also enrolled in RESTART after they 
enrolled in the Tranexamic acid for hyperacute primary 
IntraCerebral Haemorrhage (TICH-2) trial. Although the 
planned period of recruitment was extended by 1 year 
(until May 31, 2018), we did not achieve the planned 
sample size after a time-limited extension agreed by the 
funder, because only one in 12 eligible patients was 
recruited;25 therefore, we increased the duration of 
follow-up by 1 year to accrue the planned numbers of 
person-years of follow-up and primary outcome events.
268 participants were randomly assigned to start 
antiplatelet therapy and 269 to avoid antiplatelet therapy 
(figure 1), of whom all but one participant in the 
avoidance group were included in the outcome analyses.
At baseline, participants in the two treatment groups 
were on average 76 years old, approximately two-thirds 
were male, and 92% were white (table 1). 62% of 
participants had lobar intracerebral haemorrhage, 
88% had one or more previous occlusive vascular disease 
(mostly ischaemic heart disease, ischaemic stroke, or 
transient ischaemic attack), three-quarters had a history 
of high blood pressure, a quarter had diabetes, and a 
quarter had atrial fibrillation when they were randomised 
(appendix). Participants were randomly assigned to each 
Start antiplatelet 
therapy (n=268)
Avoid antiplatelet 
therapy (n=269)
Sex
Male 173 (65%) 187 (70%)
Female 95 (35%) 82 (30%)
Age*
Overall 77 (69–82) 76 (69–82)
<70 years 73 (27%) 73 (27%)
≥70 years 195 (73%) 196 (73%)
Ethnicity
White 251 (94%) 242 (90%)
Asian 12 (4%) 18 (7%)
Black 4 (1%) 5 (2%)
Other 1 (<1%) 4 (1%)
Indication for antithrombotic therapy before intracerebral haemorrhage†
At least one occlusive vascular disease
With atrial fibrillation 42 (16%) 50 (19%)
Without atrial fibrillation 194 (72%) 189 (70%)
No occlusive vascular diseases
With atrial fibrillation 19 (7%) 23 (9%)
Without atrial fibrillation 13 (5%) 7 (3%)
History of intracranial or 
extracranial haemorrhage†
22 (8%) 25 (9%)
Location of intracerebral haemorrhage*
Lobar supratentorial 166 (62%) 166 (62%)
Non-lobar 102 (38%) 103 (38%)
Time since intracerebral haemorrhage symptom onset*
Overall 80 (30–149) 71 (29–144)
1–6 days 10 (4%) 11 (4%)
7–30 days 59 (22%) 59 (22%)
>30 days 199 (74%) 199 (74%)
Probability of good 6-month outcome*19
<0·15 48 (18%) 51 (19%)
≥0·15 220 (82%) 218 (81%)
Context of enrolment
Hospital inpatient 87 (32%) 96 (36%)
Hospital outpatient 181 (68%) 173 (64%)
Participant consented 212 (79%) 213 (79%)
Proxy consented 56 (21%) 56 (21%)
Data are n (%) or median (IQR). *Variables used in the minimisation algorithm. 
†Complete list of comorbidities is in the appendix.
Table 1: Baseline characteristics
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group a median of 76 days (IQR 29–146) after intra-
cerebral haemorrhage onset. Half of the participants 
were taking aspirin, about a quarter clopidogrel, and 
approximately one-fifth oral anticoagulation at the onset 
of intracerebral haemorrhage (appendix). At baseline, 
participants’ characteristics and use of antithrombotic 
therapy were well balanced for major prognostic factors 
and potential confounders (table 1). With the exception 
of 12 participants who were ineligible because their 
intracranial haemorrhage did not extend into the brain 
parenchyma or had intracerebral haemorrhages that 
were found to be secondary to a macrovascular cause 
(one cavernous malformation, one venous thrombosis, 
and one aneurysm) and four who were taking 
anticoagulants at randomisation, the remaining 
522 (97%) participants had intracerebral haemorrhage 
without an underlying structural or macrovascular cause 
identified.
Follow-up ended on Nov 30, 2018. Four participants died 
(figure 1) before hospital discharge, and the remaining 
533 participants were followed up at hospital or clinic 
discharge. Completeness of primary care practitioner 
questionnaires (79% by post, 16% by telephone, and 4% 
by both) was 100% at all follow-up timepoints (from 
6 months to 4 years). Completeness of participant or carer 
questionnaires (60% by post, 38% by telephone, and 2% 
by both) was 99% at 6 months or at 1 year, 99% at 2 years, 
98% at 3 years, and 94% at 4 years. We obtained 1064 of 
an intended 1071 person-years of follow-up (overall 
completeness 99·3%). 
Immediate adherence to allocated treatment was good, 
with some decline over time: 99% at discharge, 93% after 
6 months or 1 year, 89% after 2 years, 86% after 3 years, 
and 82% after 4 years (appendix). Few participants 
(≤10%) used anticoagulant therapy during follow-up 
(appendix). Most participants took at least one blood-
pressure lowering drug during follow-up and achieved 
median systolic blood pressure 130 mm Hg, with good 
balance by treatment allocation (appendix).
The proportional hazards assumption was fulfilled for 
analyses of primary and secondary outcomes during 
follow-up.
For the primary outcome, 12 [4%] of 268 participants 
allocated to start antiplatelet therapy had recurrences of 
intracerebral haemorrhage compared with 23 [9%] of 
268 participants who did not start therapy (adjusted 
HR 0·51 [95% CI 0·25–1·03]; p=0·060; tables 2, 3, 
figure 2, appendix). This proportional reduction in the 
primary outcome was similar in unadjusted and 
adjusted models, and in two sensitivity analyses 
involving the addition of symptomatic stroke of 
uncertain subtype (p=0·044) or death of undetermined 
cause (p=0·048) as possible occurrences of the primary 
outcome (table 3). 30-day case fatality after recurrent 
intracerebral haemor rhage was not different between 
participants starting antiplatelet therapy (5 [42%] of 
12 participants) and those avoiding antiplatelet therapy 
(9 [39%] of 23 participants). No evidence was found of 
heterogeneity of the effects of antiplatelet therapy on the 
primary outcome in pre specified exploratory subgroup 
analyses (figure 3).
During follow-up (table 2), 104 (19%) participants 
died due to non-cardiovascular causes (n=57, 55%), 
primary or secondary outcome events (n=29, 28%), other 
cardiovascular deaths (n=16, 15%), or undetermined 
causes (n=2, 2%). 96 (18%) participants had at least one 
arterial major occlusive vascular event (including stroke 
of uncertain subtype), 46 (9%) had at least one major 
haemorrhagic event, 13 (2%) had at least one venous 
major occlusive vascular event, and 17 (3%) had a 
revascularisation procedure. 
For the composite secondary outcomes,18 18 (7%) of 
268 participants allocated to start antiplatelet therapy 
experienced major haemorrhagic events compared with 
25 (9%) of 268 participants allocated to avoid antiplatelet 
therapy (adjusted HR 0·71 [95% CI 0·39–1·30]; p=0·27); 
39 (15%) of 268 participants in the antiplatelet group had 
major occlusive vascular events compared with 38 (14%) of 
Start antiplatelet therapy 
(n=268)
Avoid antiplatelet therapy 
(n=268)
First event All events First event All events
Primary outcome
Recurrent symptomatic spontaneous 
intracerebral haemorrhage
12 (4%) 14 23 (9%) 27
Secondary outcomes
Arterial events
Major haemorrhagic events
Spontaneous or traumatic intracranial 
extracerebral haemorrhage
4 (1%) 4 3 (1%) 3
Major extracranial haemorrhage 4 (1%) 4 0 0
Major occlusive vascular events
Ischaemic stroke 19 (7%) 21 27 (10%) 28
Myocardial infarction 5 (2%) 5 8 (3%) 9
Peripheral arterial occlusion 5 (2%) 5 2 (1%) 2
Transient ischaemic attack 11 (4%) 12 18 (7%) 23
Retinal arterial occlusion 0 0 0 0
Mesenteric ischaemia 0 0 0 0
Stroke of uncertain subtype 0 0 1 (<1%) 1
Carotid, coronary, or peripheral arterial 
revascularisation procedures
12 (4%) 12 5 (2%) 5
Venous events
Deep vein thrombosis 6 (2%) 6 2 (1%) 2
Pulmonary embolism 4 (1%) 4 1 (<1%) 1
Deaths
Fatal outcome event 10 (4%) 10 19 (7%) 19
Other cardiovascular death 6 (2%) 6 8 (3%) 8
Sudden cardiac death 2 (1%) 2 0 0
Non-cardiovascular death 35 (13%) 35 22 (8%) 22
Undetermined cause 1 (<1%) 1 1 (<1%) 1
Data are n (%) or n.
Table 2: Frequencies of the first occurrence and all primary and secondary outcome events during follow-up
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268 participants in the avoidance group (1·02 [0·65–1·60]; 
p=0·92); and 54 (20%) of 268 participants in the anti-
platelet group had major haemorrhagic or occlusive 
vascular events compared with 61 (23%) of 268 participants 
in the avoidance group (0·86 [0·60–1·24]; p=0·43; table 3, 
appendix). In a sensitivity analysis, antiplatelet therapy 
did not reduce the cumulative incidence of all major 
haemorrhagic or occlusive vascular events (p=1·0). For 
the composite secondary outcome of all major vascular 
events specified in the trial protocol,4,17 antiplatelet therapy 
seemed to reduce the risk of non-fatal myocardial 
infarction, non-fatal stroke (ischaemic, haemorrhagic, or 
uncertain cause), or death from a vascular cause (adjusted 
HR 0·65 [95% CI 0·44–0·95]; p=0·025; table 3, appendix). 
We found no evidence of heterogeneity of the effects of 
antiplatelet therapy on these secondary outcomes in 
prespecified exploratory subgroup analyses (appendix) or 
in the distribution of the modified Rankin scale score 
during follow-up (appendix). Few serious adverse events 
occurred (n=11), which were neither outcomes nor 
expected complications of stroke (appendix).
Discussion
In this randomised trial of 537 survivors of an intracerebral 
haemorrhage while on antithrombotic therapy, starting 
antiplatelet therapy might have reduced the risk of 
recurrent symptomatic intracerebral haemorrhage. The 
results exclude all but a very modest increase in the risk 
of recurrent intracerebral haemorrhage with antiplatelet 
therapy, which seems too small to exceed the established 
benefits of antiplatelet therapy for secondary prevention.4 
Therefore, starting antiplatelet therapy seems to be safe 
and might be beneficial in patients who survived a 
median of 76 days after intracerebral haemorrhage, most 
of whom had good functional ability at baseline and a 
higher probability of good functional outcome at 6-month 
follow up (table 1, appendix).19 Our findings, alongside 
published observational studies,9–14 provide reassurance 
about the use of long-term antiplatelet therapy in a range 
of patients after intracerebral haemorrhage associated 
with antithrombotic therapy.
RESTART is the first randomised trial comparing 
starting versus avoiding antiplatelet therapy after 
Start 
antiplatelet 
therapy 
(n=268)
Avoid 
antiplatelet 
therapy 
(n=268)
Log-rank 
test 
p value
Unadjusted analysis Adjusted analysis
HR (95% CI) p value HR (95% CI) p value
Primary outcome
Recurrent symptomatic spontaneous intracerebral haemorrhage 12 23 0·057 0·51 (0·26–1·03) 0·062 0·51 (0·25–1·03) 0·060
Sensitivity analyses of the primary outcome
Recurrent symptomatic spontaneous intracerebral haemorrhage or symptomatic 
stroke of uncertain subtype
12 24 0·041 0·49 (0·25–0·99) 0·046 0·49 (0·24–0·98) 0·044
Recurrent symptomatic spontaneous intracerebral haemorrhage or death of 
undetermined cause
13 25 0·047 0·51 (0·26–1·00) 0·051 0·51 (0·26–0·99) 0·048
Secondary outcomes
All major haemorrhagic events (all types of symptomatic spontaneous or traumatic 
intracranial haemorrhage, or symptomatic major extracranial haemorrhage)
18 25 0·27 0·71 (0·39–1·30) 0·27 0·71 (0·39–1·30) 0·27
All major occlusive vascular events (ischaemic stroke; myocardial infarction; 
mesenteric ischaemia; peripheral arterial occlusion; deep vein thrombosis; pulmonary 
embolism; or carotid, coronary, or peripheral arterial revascularisation procedures)
39 38 0·97 1·01 (0·65–1·58) 0·97 1·02 (0·65–1·60) 0·92
All major haemorrhagic or occlusive vascular events 54 61 0·42 0·86 (0·60–1·24) 0·42 0·86 (0·60–1·24) 0·43
Major occlusive vascular events* 45 52 0·39 0·84 (0·56–1·25) 0·39 0·84 (0·56–1·25) 0·39
Major vascular events (as defined by the Antithrombotic Trialists’ Collaboration) 45 65 0·026 0·65 (0·45–0·95) 0·027 0·65 (0·44–0·95) 0·025
HR=hazard ratio. *As defined in the trial protocol.
Table 3: Risks of first occurrence of primary and secondary outcome events during follow-up
Figure 2: Kaplan-Meier plot of the first occurrence of recurrent symptomatic intracerebral haemorrhage
Numbers at risk refer to survivors under follow-up at the start of each year according to treatment allocation. 
Cumulative events indicate the participants in follow-up with a first event. HR=hazard ratio.
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intracerebral haemorrhage,7 and provides more reliable 
esti mates of the effects of antiplatelet therapy than 
previous observational studies.9–14 We minimised selection 
bias by using central, computerised random sequence 
generation and concealing allocation on the web 
application until all baseline data were entered. The 
recruited participants were comparable to European 
hospital-based and population-based cohorts of survivors 
of intracerebral haemorrhage who had previously taken 
antithrombotic therapy.3 Blood pressure was controlled 
for both groups throughout follow-up: half of the 
participants had a systolic blood pressure below the 
recommended target in the UK national stroke guideline 
and antihypertensive drug use was similar between 
groups. We minimised attrition bias by achieving 
99·3% completeness of follow-up. The risk of recurrent 
intracerebral haemorrhage was at the lower end of the 
ranges reported in cohort studies,1 but similar to the 
0·61–1·20% annual rates observed with cilostazol or 
aspirin use in the recent PICASSO trial.26 The risk of 
gastrointestinal haemorrhage was low (table 2), possibly 
due to the prevalence of proton pump inhibitor use in a 
contemporary population of older stroke survivors.27 We 
masked outcome assessors to treatment allocation group 
and receipt of antithrombotic therapy, and used objective 
definitions of major outcomes and independent 
verification, to reduce misclassification of haemorrhagic 
and occlusive vascular events, and reduce bias that can 
arise in outcome assessment when treatment allocation 
is open.28 We prespecified our outcomes and methods of 
analysis,17 and report these according to our protocol 
and statistical analysis plan.18 We also did prespecified 
exploratory analyses to investigate the effects of anti-
platelet therapy according to brain imaging biomarkers 
that are often observed in clinical practice, which we 
report separately.29
RESTART has some limitations. We intended to recruit 
720 participants and follow them up for 2 years, but we 
recruited only 537 people (75% of our target). Investigators 
managed to recruit only one in 12 eligible patients; the 
remainder were not randomised because 28% of patients 
were too unwell when approached, 26% of patients’ 
physicians were certain about whether or not to use 
antiplatelet therapy, 9% of patients declined, 7% of 
patients were started on oral antico agulation, and 
30% were not recruited for other reasons.25 Because of 
slow recruitment, we did a stepped wedge cluster 
randomised study within this trial at 72 of the sites to 
investigate whether stroke audit data extracts could boost 
recruit ment; however, this strategy was not successful.30
Figure 3: Prespecified exploratory subgroup analyses of the risk of first recurrent symptomatic intracerebral haemorrhage
Overall
Type of antithrombotic drug regimen before  
intracerebral haemorrhage 
       Anticoagulant with or without antiplatelet                 
Antiplatelet alone
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     No
    Yes
Predicted probability of good outcome at 6 months     
<0·15·
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≥70
Other
Aspirin
Antiplatelet drug(s) that the participant’s clinician would start
Time since intracerebral haemorrhage symptom onset 
≤median time from symptom onset
>median time from symptom onset
Non-lobar
Lobar
Intracerebral haemorrhage location
12/268 (4%)
10/221 (5%)
2/47 (4%)
4/61 (7%)
8/207 (4%)
9/220 (4%)
3/48 (6%)
11/195 (6%)
1/73 (1%)
4/119 (3%)
8/149 (5%)
5/139 (4%)
7/129 (5%)
4/102 (4%)
8/166 (5%)
23/268 (9%)
16/211 (8%)
7/57 (12%)
8/73 (11%)
15/195 (8%)
15/217 (7%)
8/51 (16%)
18/195 (9%)
5/73 (7%)
10/119 (8%)
13/149 (9%)
9/128 (7%)
14/140 (10%)
12/102 (12%)
11/166 (7%)
0·51 (0·25–1·03)
0·59 (0·27–1·30)
0·33 (0·07–1.59)
0·51 (0·15–1·72)
0·51 (0·22–1·22)
0·59 (0·26–1·36)
0·36 (0·09–1·37)
0·60 (0·28–1·26)
0·20 (0·02–1·74)
0·41 (0·13–1·32)
0·58 (0·24–1·41)
0·52 (0·17–1·54)
0·51 (0·21–1·27)
0·31 (0·10–0·96)
0·75 (0·30–1·87)
0·52
>0·99
0·53
0·36
0·64
>0·99
0·23
Favours start Favours avoid
0·1 0·25 0·5 1·0 2·0 4·0
pinteractionEvents/participants (%) Adjusted HR (95% CI)
Start antiplatelet 
therapy
Avoid antiplatelet 
therapy
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As in many other randomised trials of intracerebral 
haemorrhage, most participants were male, which might 
be because of their propensity to be invited or consent 
rather than differences in incidence or outcome of 
intracerebral haemorrhage compared with women.31,32 
Although we did not mask the assigned treatment to 
participants and physicians, the outcomes were objective 
and adjudicated masked to treatment allocation, which 
minimises bias.33 Antiplatelet regimens used were mostly 
monotherapy, so the effects of dual antiplatelet therapy 
remain uncertain. Adherence to the allocated treatment 
declined over time but was more than 80% even after 
4 years of follow-up. Although the sample size was smaller 
than intended and multiple statistical comparisons were 
done, we prespecified our primary outcome and main 
hypothesis, and regarded analyses of secondary outcomes 
and effects in subgroups as exploratory.
Platelets are the dominant contributor to thrombus 
formation in the arterial circulation, so antiplatelet therapy 
predominantly prevents arterial thrombosis. We included 
venous occlusive events in our composite secondary 
outcome of all haemorrhagic or occlusive vascular events 
because randomised trials suggested that antiplatelet 
therapy might prevent venous occlusive events,34 but this 
benefit was not evident in this trial. However, in this trial, 
antiplatelet therapy did reduce a composite of major 
vascular events used by the Antithrombotic Trialists’ 
Collaboration (that did not include venous occlusive 
events), with a proportionate reduction similar to the 
effects of aspirin for secondary prevention in their meta-
analysis.4
Our finding that antiplatelet therapy might have reduced 
the risk of recurrent intracerebral haemorrhage was 
unexpected. Although we cannot rule out a random effect, 
this observation might not be as counterintuitive as it first 
seems. First, arterial thrombosis can trigger haemorrhage.35 
Second, more spontaneous intracerebral haemorrhages 
than expected might be due to haemor rhagic trans-
formation of ischaemic stroke. Finally, inflammation 
might be a key mechanism underlying intracerebral 
haemorrhage (as is thought to be the case for intracranial 
aneurysms). These potential mechanisms underlying 
RESTART’s findings merit further investigation.
Our findings have several implications for future 
research. We will continue follow-up of the surviving 
participants in RESTART for another 2 years to improve 
precision of effect estimates, especially after 2 years of 
follow-up, and observe whether adherence changes after 
the trial result is known. Ongoing randomised trials, such 
as RESTART-Fr (NCT02966119, intended sample size 280) 
and STATICH (NCT03186729, intended sample size 250), 
might help to confirm or refute the effects of antiplatelet 
therapy seen in RESTART.7 A prospectively planned 
individual patient data meta-analysis of RESTART and 
these trials, and in due course a larger randomised trial, 
could increase power to detect the overall effects of 
antiplatelet therapy in these patients and in subgroups of 
interest with further investigation at earlier times after 
intracerebral haemorrhage and of heterogeneity of 
treatment effect by imaging features.29 RESTART’s 
findings also support the conduct of randomised trials 
of oral anticoagulation for survivors of intracerebral 
haemorrhage with atrial fibrillation, for whom there is 
some justification for the use of antiplatelet therapy as a 
comparator.36
In summary, RESTART excluded all but a very modest 
increase in the risk of recurrent intracerebral haemor-
rhage with antiplatelet therapy, which seemed too small 
to exceed the established benefits of antiplatelet therapy 
for secondary prevention of major vascular events 
(video). Antiplatelet therapy might have reduced the 
recurrence of intracerebral haemorrhage. These findings 
provide reassurance about the use of antiplatelet 
therapy for similar patients in clinical practice. Ongoing 
randomised trials, their meta-analysis with RESTART, 
and an adequately powered definitive randomised trial 
should be done to strengthen the evidence.
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